score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.2387	331.0	1.6e-05	0.0		Putatively Actionable	Dabrafenib + Trametinib	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Tafinlar [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2018.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202806s008lbl.pdf	Putatively Actionable	Panitumumab	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0.0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	0	137.0	0.2044	1.0	BRAF p.V600E (Missense)	1.0	MEL-IPI_Pat03	MEL-IPI_Pat03-Tumor-SM-4DJZY	MEL-IPI_Pat03-Normal-SM-4NFU5
Investigate Actionability - High	Guideline			Rearrangement	COL1A1	Fusion	COL1A1--MALAT1			0.0	0.0		Investigate Actionability - High	Imatinib	Targeted therapy	Imatinib has shown clinical activity against localized and metastatic DFSP tumors containing t(17;22)(q22;q13).	National Comprehensive Cancer Network. Dermatofibrosarcoma NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/dfsp_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/dfsp_blocks.pdf												0				COL1A1--MALAT1 Fusion	0.0	MEL-IPI_Pat03		
Investigate Actionability - High	Clinical evidence			Mutational Burden	High Mutational Burden								Investigate Actionability - High	Ipilimumab	Immunotherapy	In a study of malignant melanoma using a discovery cohort of 25 patients and a validation cohort of 39 patients, a significantly higher muational burden was seen in patients with a long-term clinical benefit vs. patients with minimal or no benefit to ipilimumab treatment.	Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189-99.	https://doi.org/10.1056/NEJMoa1406498												0				 mutations per Mb		MEL-IPI_Pat03		
Investigate Actionability - High	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.P209S	0.0333	210.0	0.0	0.0		Investigate Actionability - High	PU-H71	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821							Investigate Actionability - Low	0.0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1	0	290.0	0.0448	0.961	JAK1 p.P209S (Missense)		MEL-IPI_Pat03	MEL-IPI_Pat03-Tumor-SM-4DJZY	MEL-IPI_Pat03-Normal-SM-4NFU5
Investigate Actionability - High	Preclinical			Somatic Variant	AKT3	Missense	p.P449S	0.0563	231.0	0.0	0.0		Investigate Actionability - High	MK-2206	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230												0	128.0	0.1016	0.9108	AKT3 p.P449S (Missense)	0.0	MEL-IPI_Pat03	MEL-IPI_Pat03-Tumor-SM-4DJZY	MEL-IPI_Pat03-Normal-SM-4NFU5
Investigate Actionability - High			Clinical evidence	Somatic Variant	STAG2	Splice Site	p.K372K	0.0514	370.0	0.0	0.0														Investigate Actionability - High	0.0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0	129.0	0.0	0.8869	STAG2 p.K372K (Splice Site)		MEL-IPI_Pat03	MEL-IPI_Pat03-Tumor-SM-4DJZY	MEL-IPI_Pat03-Normal-SM-4NFU5
Investigate Actionability - High			Inferential	Aneuploidy	Whole genome doubling																				Investigate Actionability - High	0.0	WGD was associated with adverse survival pan-cancer in patients with advanced disease and in cancers with heterogeneous clinical outcomes, even following the development of metastasis.	Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and prognosis of advanced cancers Nat Genet. 2018; 50(8):1189-1195.	https://doi.org/10.1038/s41588-018-0165-1	0						MEL-IPI_Pat03		
Investigate Actionability - Low	FDA-Approved			Somatic Variant	TSC1	Missense	p.E801K	0.0852	270.0	0.0	0.0		Investigate Actionability - Low	Everolimus	Targeted Therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Everolimus [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2012.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022334s016lbl.pdf												0	223.0	0.0224	0.9999	TSC1 p.E801K (Missense)		MEL-IPI_Pat03	MEL-IPI_Pat03-Tumor-SM-4DJZY	MEL-IPI_Pat03-Normal-SM-4NFU5
Investigate Actionability - Low	FDA-Approved			Somatic Variant	TSC2	Missense	p.V118I	0.0272	147.0	0.0	0.0		Investigate Actionability - Low	Everolimus	Targeted Therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Everolimus [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2012.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022334s016lbl.pdf												0	0.0	0.0	0.0	TSC2 p.V118I (Missense)		MEL-IPI_Pat03	MEL-IPI_Pat03-Tumor-SM-4DJZY	MEL-IPI_Pat03-Normal-SM-4NFU5
Investigate Actionability - Low	Clinical evidence	Clinical evidence		Somatic Variant	BRCA2	Missense	p.E38K	0.047	659.0	0.0	0.0		Investigate Actionability - Low	Pembrolizumab + Nivolumab	Immunotherapy	Responders were enriched for mutation in BRCA2 mutations, mostly nonsense mutations. 6 of 21 responders had BRCA2 vs. 1 of 17 nonresponders.	Hugo W, Zaretsky JM, Sun L, et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma Cell. 2016; 165(1):35-44.	https://doi.org/10.1016/j.cell.2016.02.065	Investigate Actionability - Low	Olaparib	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677						0	48.0	0.0417	0.2067	BRCA2 p.E38K (Missense)		MEL-IPI_Pat03	MEL-IPI_Pat03-Tumor-SM-4DJZY	MEL-IPI_Pat03-Normal-SM-4NFU5
Investigate Actionability - Low	Clinical evidence			Somatic Variant	MSH6	Splice Site	p.G1216R	0.0554	397.0	0.0	0.0		Investigate Actionability - Low	Pembrolizumab	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596												0	134.0	0.0448	0.9278	MSH6 p.G1216R (Splice Site)		MEL-IPI_Pat03	MEL-IPI_Pat03-Tumor-SM-4DJZY	MEL-IPI_Pat03-Normal-SM-4NFU5
Biologically Relevant				Rearrangement	EGFR	Fusion	FRMD8--EGFR			0.0	0.0																			0				FRMD8--EGFR Fusion		MEL-IPI_Pat03		
Biologically Relevant				Copy Number	EML4	Deletion				0.0	0.0																			0				EML4 Deletion		MEL-IPI_Pat03	MEL-IPI_Pat03-Tumor-SM-4DJZY	
Biologically Relevant				Microsatellite Stability	Supporting variants		MSH6 p.G1216R (Splice Site), PRDM2 p.703_704insP (Insertion), MSH3 p.AAAAAA52del (Deletion), MSH3 p.PPA66del (Deletion)																							0				Supporting variants: MSH6 p.G1216R (Splice Site), PRDM2 p.703_704insP (Insertion), MSH3 p.AAAAAA52del (Deletion), MSH3 p.PPA66del (Deletion)		MEL-IPI_Pat03		
Biologically Relevant				Mutational Signature	COSMIC Signature 11		0.947																							0				COSMIC Signature 11 (95%)		MEL-IPI_Pat03		
